Multiple Myeloma

>

Latest News

In the analysis comparing D-VRd with other regimens for MRD-negative CR rate, there was an 81% probability that it was favorable vs Isa-VRd.
Which Therapy Has the Best Efficacy in Transplant-Ineligible NDMM?

October 1st 2025

D-VRd had a 72% chance of providing superior PFS outcomes vs isatuximab plus VRd in patients with transplant-ineligible NDMM.

Treatment with anito-cel shows a predictable and manageable safety profile among those with relapsed/refractory multiple myeloma in the iMMagine-1 trial.
Anito-cel Yields Enduring Efficacy in Relapsed/Refractory Multiple Myeloma

September 30th 2025

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma
The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

September 27th 2025

The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.
Dara-KRd Regimen Displays Prolonged PFS in Newly Diagnosed Multiple Myeloma

September 22nd 2025

CEPHEUS Highlights Efficacious, Safe Regimen for Transplant-Ineligible/Deferred Multiple Myeloma
CEPHEUS Highlights Efficacious, Safe Regimen for Transplant-Ineligible/Deferred Multiple Myeloma

September 21st 2025

Latest CME Events & Activities

More News

A panel of 4 experts on multiple myeloma seated at a long table

Treatment Decision-Making in Early-Relapse MM

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
October 31st 2023

Expert perspectives on treatment decision-making in early-relapse multiple myeloma and the efficacy of CAR T-cell therapy.

A panel of 4 experts on multiple myeloma seated at a long table

Recent Data in the Management of Early-Relapse Multiple Myeloma

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
October 31st 2023

A panel of oncologists give an overview of clinical trial data surrounding the management of early-relapse multiple myeloma.

Jeffrey A. Zonder, MD, an expert on multiple myeloma

Outcomes After Biochemical or Clinical Progression in Patients with MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 27th 2023

Jeffrey A. Zonder, MD, reviews data on patient outcomes following biochemical or clinical progression in multiple myeloma.

Jack Khouri, MD, an expert on multiple myeloma

Cross Q&A: Efficacy of CAR T-Cell Therapy in MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 27th 2023

The expert panel discusses the efficacy and durability of response of ciltacabtagene autoleucel in patients with multiple myeloma.

Preclinical Characterization of ISB 1342, a CD38 × CD3 T-Cell Engager for Relapsed/Refractory Multiple Myeloma

Preclinical Characterization of ISB 1342, a CD38 × CD3 T-Cell Engager for Relapsed/Refractory Multiple Myeloma

American Society for Transplantation and Cellular Therapy
October 25th 2023

ISB 1342 has shown improved safety and efficacy for patients with relapsed/refractory multiple myeloma.

Mayo Clinic and UT Southwestern “Face Off” Over Multiple Myeloma and CML

Mayo Clinic and UT Southwestern “Face Off” Over Multiple Myeloma and CML

ONCOLOGY Staff
October 20th 2023

UT Southwestern and Mayo Clinic debated over current treatment options in chronic myeloid leukemia and multiple myeloma.

Jack Khouri, MD, an expert on multiple myeloma

CARTITUDE-4: Cilta-Cel in Lenalidomide-Refractory MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 20th 2023

Jack Khouri, MD, discusses phase 3 results from the CARTITUDE-4 study investigating ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Andrew Kin, MD, an expert on multiple myeloma

Cross Q&A: Treatment Considerations for Ixa-Pom-Dex in Multiple Myeloma

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 20th 2023

Following a review of data from the ALLIANCE A061202 study, experts on multiple myeloma discuss treatment considerations for patients being treated with ixazomib, pomalidomide, and dexamethasone.

Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma

Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma

ONCOLOGY Staff
October 19th 2023

Fred Hutch and City of Hope "Face Off" regarding presentations focusing on multiple myeloma and chronic myeloid leukemia.

A panel of 4 experts on multiple myeloma seated at a long table

Unmet Needs and Future Perspectives on Treating Patients With Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD
October 18th 2023

Concluding their comprehensive discussion on treating patients with multiple myeloma, the expert panel discusses unmet needs and looks to the future of treatment.

A panel of 4 experts on multiple myeloma seated at a long table

Patient Profile 3: A 68-Year-Old With Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD
October 18th 2023

The panel presents the case of a 68-year-old man with multiple myeloma and offers their initial impressions.

Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma

Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma

Ludovic Saba, MD;Kevin S. Landau, MD;Silvia Bunting, MD;Chakra P. Chaulagain, MD
October 17th 2023

Investigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.

Andrew Kin, MD, an expert on multiple myeloma

ALLIANCE A061202: Ixazomib Plus Pomalidomide and Dexamethasone in Multiple Myeloma

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 13th 2023

Andrew Kin, MD, reviews data on the addition of ixazomib to pomalidomide and dexamethasone in patients with multiple myeloma who progressed on lenalidomide in the first line.

The host of Cancer Network's Face-Off program shown with an introductory slide

Team Introductions: MM Experts From Karmanos Cancer Institute and Cleveland Clinic

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 13th 2023

A panel of experts on multiple myeloma from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in multiple myeloma.

A panel of 4 experts on multiple myeloma seated at a long table

Patient Profile 2: A 75-Year-Old With Multiple Myeloma With Lytic Disease

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD
October 11th 2023

Shared insights on the patient profile of a 75-year-old woman with multiple myeloma with confirmed lytic disease.

A panel of 4 experts on multiple myeloma seated at a long table

Patient Profile 1: A 70-Year-Old With Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD
October 11th 2023

The expert panel presents the patient case of a 70-year-old man with multiple myeloma and discusses treatment decisions.

Experts on MM

CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple Myeloma

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
October 10th 2023

Panelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.

Looking Ahead in the Multiple Myeloma Treatment Landscape

Looking Ahead in the Multiple Myeloma Treatment Landscape

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
October 4th 2023

Experts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.

Expert Perspectives on Quadruplet Therapy Regimens for Patients With Multiple Myeloma

Expert Perspectives on Quadruplet Therapy Regimens for Patients With Multiple Myeloma

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
October 4th 2023

The panel shares some personal experiences with treating patients with multiple myeloma with a quadruplet therapy regimen.

A panel of 4 experts on multiple myeloma seated at a long table

RedirecTT-1: Teclistamab Plus Talquetamab in Relapsed/Refractory MM

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD
October 4th 2023

An overview of the RedirecTT-1 study investigating teclistamab plus talquetamab in patients with relapsed/refractory multiple myeloma.

A panel of 4 experts on multiple myeloma seated at a long table

Talquetamab for Patients With Relapsed/Refractory MM

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD
October 4th 2023

Continuing discussion on bispecific antibodies, attention turns to talquetamab and the MonumenTAL-1 clinical trial for patients with relapsed/refractory multiple myeloma.

Experts on MM

Debate on Efficacy and Patient Selection With Ixa-Pom-Dex in Relapsed/Refractory MM

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
October 3rd 2023

Leading experts discuss the potential benefits and challenges of using ixazomib pomalidomide-dexamethasone as a treatment option for relapsed myeloma patients, considering factors like efficacy, overall survival, and patient demographics.

Experts on MM

Ixa-Pom-Dex as Second-Line Therapy in Relapsed/Refractory MM: Alliance A061202

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
October 3rd 2023

Rahul Banerjee, MD, FACP, discusses the Alliance A061202 trial, presenting the potential benefits and red flags of using ixazomib-pomalidomide-dexamethasone combination in relapsed myeloma treatment.

Data suggest a role for TIGIT blockade or CD25-positive cell depletion to enhance teclistamab’s efficacy in relapsed/refractory multiple myeloma.

Teclistamab Produces Responses in Pretreated R/R Multiple Myeloma

Jordyn Sava
October 2nd 2023

Data suggest a role for TIGIT blockade or CD25-positive cell depletion to enhance teclistamab’s efficacy in relapsed/refractory multiple myeloma.

Investigators of a phase 1a trial report high objective response rates in patients receiving forimtamig for relapsed/refractory multiple myeloma, including those with high-risk cytogenetics and extra medullary disease.

Forimtamig Yields Sustained Responses in R/R Multiple Myeloma

Tony Berberabe, MPH
October 2nd 2023

Investigators of a phase 1a trial report high objective response rates in patients receiving forimtamig for relapsed/refractory multiple myeloma, including those with high-risk cytogenetics and extra medullary disease.

BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents.

Immunotherapy Sequences May Lead to Disease Resistance/Relapse in Myeloma

Conor Killmurray
October 1st 2023

BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents.

Pomalidomide plus bortezomib and dexamethasone confers a larger progression-free survival benefit than bortezombib plus dexamethasone among patients with relapsed/refractory multiple myeloma in the phase 3 OPTIMISMM trial.

Pomalidomide Combo Yields PFS/OS Benefits in R/R Multiple Myeloma

Kyle Doherty
October 1st 2023

Pomalidomide plus bortezomib and dexamethasone confers a larger progression-free survival benefit than bortezombib plus dexamethasone among patients with relapsed/refractory multiple myeloma in the phase 3 OPTIMISMM trial.

APOBEC mutational activity appears to be prognostic in patients with newly diagnosed multiple myeloma or precursor diseases who receive daratumumab quadruplets, according to Kylee Maclachlan, MBChB, PhD.

Daratumumab Combos Are Effective in NDMM Despite Relapses in Subgroups

Russ Conroy
September 29th 2023

APOBEC mutational activity appears to be prognostic in patients with newly diagnosed multiple myeloma or precursor diseases who receive daratumumab quadruplets, according to Kylee Maclachlan, MBChB, PhD.

When teclistamab was evaluated in a real-world setting, investigators determined that efficacy was similar between that and the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.

Real-world Teclistamab Use Finds Comparable Efficacy With MajesTec-1 in Multiple Myeloma

Ariana Pelosci
September 29th 2023

When teclistamab was evaluated in a real-world setting, investigators determined that efficacy was similar between that and the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.

Investigators report a low rate of high-grade hematologic adverse effects following treatment with induction Dara-KRd and consolidation double transplant in patients with high-risk, newly diagnosed multiple myeloma.

Data Confirm Dara-KRd/Double Transplant Benefit in Newly Diagnosed Myeloma

Hayley Virgil
September 29th 2023

Investigators report a low rate of high-grade hematologic adverse effects following treatment with induction Dara-KRd and consolidation double transplant in patients with high-risk, newly diagnosed multiple myeloma.

<1
...
161718192021222324
...
66>